Bayer’s asundexian cut recurrent stroke risk by 26%, but can new AHA evidence strengthen its global approval prospects?
Bayer is preparing new analyses spanning stroke prevention, heart failure and chronic kidney disease for AHA Scientific Sessions 2026. The presentations follow China's approval of asundexian and expanding US indications for finerenone, but most of the newly scheduled subgroup findings remain undisclosed.
